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accounting for 22.3% (US$81.8 billion) and
7.2% (US$36.6 billion), respectively, of all
Medicare fee-for-service spending in 2018.7 8
Medicare expenditures for people with CKD
have risen at a rate higher than expenditures
for the general Medicare population and have
been found costlier for people with CKD and
comorbid heart failure or diabetes (type 1 or
2), highlighting clear clinical and economic
rationales for early identification and treatment intervention to limit CKD progression
in all populations, particularly in people with
T2D and cardiovascular risk factors.7
Early diagnosis of CKD may prove vital in
people with T2D, allowing for more immediate clinical care, and identification of the
risks for progression to ESKD. This may be
Caribbean/
particularly important in Afro-
African-American, Hispanic and Asian populations, who tend to have a higher risk of
CKD progression relative to White people;
the increased risk may be explained in part
by factors such as higher blood pressure and
increased prevalence of T2D and cardiovascular disease in these populations.9 However,
diagnosis of CKD is challenging because of
the lack of symptoms during its early stages.10
Other potential factors that hinder early
detection of CKD include a lack of awareness of CKD in the general population, poor
adherence to clinical guidelines, and the variINTRODUCTION
Type 2 diabetes (T2D) is the leading cause of ation in screening and treatment incentives
10
chronic kidney disease (CKD) and end-stage by practice and by country.
1–3
Diagnosis and determination of the severity of
kidney disease (ESKD).
More than one-
third of people with T2D also have CKD,4 and CKD relies on routine measurement of reduced
this population is associated with a 10-fold estimated glomerular filtration rate (eGFR; <60
2
or greater increase in all-
cause mortality mL/min/1.73 m ) for at least 3 months and/
5
compared with T2D alone. Furthermore, or persistently elevated albuminuria (urine
CKD progression leads to ESKD, which is albumin-to-creatinine ratio (UACR)), to assess
irreversible and fatal in the absence of kidney the overall kidney function and the presence
1 2 11
As such, the
replacement therapy.6 CKD and ESKD are of kidney damage, respectively.
associated with high economic burden, Kidney Disease: Improving Global Outcomes
ABSTRACT

Albuminuria is useful for early screening and diagnosis of
kidney impairment, especially in people with pre-diabetes
or type 2 diabetes (T2D), which is the leading cause
of chronic kidney disease (CKD) and end-stage kidney
disease (ESKD), associated with increased mortality, poor
cardiovascular outcomes, and high economic burden.
Identifying patients with CKD who are most likely to
progress to ESKD permits timely implementation of
appropriate interventions. The early stages of CKD are
asymptomatic, which means identification of CKD relies
on routine assessment of kidney damage and function.
Both albuminuria and estimated glomerular filtration
rate are measures of kidney function. This review
discusses albuminuria as a marker of kidney damage
and cardiorenal risk, highlights the importance of early
screening and routine testing for albuminuria in people
with T2D, and provides new insights on the optimum
management of CKD in T2D using albuminuria as a target
in a proposed algorithm. Elevated urine albumin can
be used to detect CKD in people with T2D and monitor
its progression; however, obstacles preventing early
detection exist, including lack of awareness of CKD in the
general population, poor adherence to clinical guidelines,
and country-level variations in screening and treatment
incentives. With albuminuria being used as an entry
criterion and a surrogate endpoint for kidney failure in
clinical trials, and with novel treatment interventions
available to prevent CKD progression, there is an urgent
need for early screening and diagnosis of kidney function
decline in people with T2D or pre-diabetes.
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(KDIGO) CKD working group uses a combination of
eGFR and UACR categories in its risk stratification tool for
predicting CKD outcomes (figure 1).2 Clinical guidelines
in Europe, USA and other countries recommend yearly
screening of albuminuria and eGFR in people with T2D.11 12
However, real-world data suggest that rates of albuminuria
testing in clinical practice are suboptimal,4 resulting in a
gross underestimation of the risk of CKD in people with
T2D. Routine assessment of both screening for CKD prognosis and management was further emphasized in a recent
systematic review that showed an association between the
prevalence of comorbidities in CKD and an increase in
albuminuria severity.13 While CKD is common, only a small
proportion of patients were classified as high risk or very
high risk according to the KDIGO classification, highlighting
key gaps in the burden and outcomes of CKD defined by
the KDIGO 2012 guideline.13 With novel treatment interventions now available that can slow CKD progression, there
is an urgent need for the early screening and diagnosis of
kidney function decline in people with T2D. To this end, this
review discusses albuminuria as a marker of kidney damage
and cardiorenal risk, and the importance of earlier and more
frequent screening.
ALBUMINURIA AS A MARKER OF KIDNEY DAMAGE AND
CARDIORENAL RISK
UACR can be easily measured by spot urine samples,
preferably obtained from the first morning void.2 Despite
strong recommendations to screen for UACR in patients
2

with T2D, studies show testing for UACR is underused
compared with eGFR testing: the Awareness, Detection
and Drug Therapy in Type 2 Diabetes and Chronic Kidney
Disease study reports 85% of patients undergo eGFR
testing versus 47% with UACR determination14; similar
patterns for underutilization of eGFR and UACR testing
were noted in the Center for Kidney Disease Research,
Education, and Hope (CURE-CKD) registry of people
with T2D at risk for CKD.15 16 Addressing this discord in
eGFR and UACR testing is important because detectable
increases in albuminuria generally occur before a decline
in eGFR and early changes could indicate signs of kidney
disease.17 18 Similarly, albuminuria has been associated
with an elevated risk of hospitalization in older adults
with and without diabetes (type 1 or 2), further emphasizing the importance of albuminuria measurement as a
marker.19
As well as being useful for the early detection of CKD
in people with T2D, elevated UACR levels can also be
used to monitor CKD progression.2 The ability of albuminuria to predict the progression of kidney disease is
irrespective of eGFR,20 with the relative risks of ESKD,
acute kidney injury, and progressive CKD increasing
with elevating levels of albuminuria.17 20 21 In general,
lower eGFR and higher levels of albuminuria (>300
mg/g) independently predict faster progression to
ESKD among patients with stage 3 CKD (eGFR 30–60
mL/min/1.73 m2).20 While kidney function decline is
a continuum, recognized albuminuria categories in
BMJ Open Diab Res Care 2022;10:e002806. doi:10.1136/bmjdrc-2022-002806
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Figure 1 Prognosis of CKD by GFR and albuminuria categories. Green: low risk (if no other markers of kidney disease,
no CKD); yellow: moderately increased risk; orange: high risk; red: very high risk. Reproduced with permission from Kidney
Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney
Disease.1 A, albuminuria category; CKD, chronic kidney disease; G, GFR category; GFR, glomerular filtration rate.
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hypertension may elevate the UACR independent of
kidney damage.11
While elevated albuminuria can be indicative of
CKD, incremental increases in albuminuria are associated with corresponding increases in cardiorenal
risk.24 Concomitant CKD and T2D is an independent
risk factor for cardiovascular events, with this population being approximately three times more likely to
die from cardiovascular-related causes than those with
T2D alone, and almost six times more likely to die from
cardiovascular-related causes than those with neither
T2D nor CKD.5 Based on a report from the Framingham Heart Study, the presence of albuminuria is
associated with a higher risk of incident heart failure,
specifically heart failure with reduced ejection fraction, in the general population. In patients with T2D
and kidney disease, patients with an increased level
of baseline albuminuria had a higher risk for heart
failure compared with those with low albuminuria. In
addition, the Reduction of Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan (RENAAL)
study showed that reduction in albuminuria by 50%
was associated with reduced risks of cardiovascular
events by 18% and heart failure by 27%.24 People with
T2D and moderately to severely increased albuminuria have an approximately threefold, fourfold, and
fivefold greater risk of myocardial infarction, cardiovascular death and hospitalization for heart failure,
respectively, than those with T2D alone.25 A recent
study (n=512 700) showed that early CKD in people
with diabetes may shorten life expectancy by 16 years,
compared with 6 years for early CKD without diabetes

Figure 2 Life expectancy in people with early CKD, T2D, and early CKD in T2D. The reference group consisted of participants
with neither diabetes nor CKD. Early CKD was defined as CKD stages 1–3 without diabetes. Diabetes was defined as T2D
without CKD. Early CKD in T2D was defined as diabetes with early CKD stages 1–3. Reproduced with permission from Kidney
International.26 CKD, chronic kidney disease; T2D, type 2 diabetes.
BMJ Open Diab Res Care 2022;10:e002806. doi:10.1136/bmjdrc-2022-002806
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CKD include: A1 (normal to mildly increased albuminuria), defined as UACR <30 mg/g; A2 (moderately
increased albuminuria), defined as UACR 30–300
mg/g; and A3 (severely increased albuminuria),
defined as UACR >300 mg/g (figure 1).2
Large interindividual variability in kidney decline
has been documented. The UK Prospective Diabetes
Study found that 38% of people with T2D developed
albuminuria and 29% developed renal impairment,
with many developing one outcome but not the
other.22 Thus, some patients with T2D may have CKD
without the presence of albuminuria,22 suggesting that
the assessment of albuminuria alone may not optimally
identify people with T2D who are at high risk of kidney
impairment. An additional challenge in screening for
CKD in people with T2D is the occurrence of hyperfiltration with normal creatinine/eGFR and without
albuminuria. Results from a large observational study
indicate that in T2D, both hyperfiltration and high-
normal eGFR levels are associated with increased risk
of mortality, independent of confounders that may
directly impact mortality or GFR estimation.23 Routine
assessment of both albuminuria and eGFR is warranted
in these patients. Also, it is important to note that
elevated albumin in the urine may be indicative of
other disorders. Albuminuria is the earliest marker
of other glomerular diseases, and may be elevated
in hypertensive nephrosclerosis; it is also associated
with hypertension, obesity, and vascular disease.2
Furthermore, exercise within 24 hours of albuminuria
assessment, infection, fever, congestive heart failure,
marked hyperglycemia, menstruation, and marked
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TREATMENT AND PREVENTION OF CKD
The ability to identify patients with CKD most likely to
progress to ESKD would permit timely implementation
of appropriate interventions. Progression of CKD poses
a significant impact on the health and quality of life of
affected patients,27 28 as well as a large financial burden.7
Efforts to improve care of patients with CKD should
focus on reducing the incidence of kidney failure (often
defined as a composite of outcomes including sustained
low/declining GFR and clinical outcomes of transplantation, dialysis or death from kidney failure), and should
provide more affordable treatment options, as well as
improving access to kidney transplantation and home
dialysis.27 28
Early intensive glycemic control can reduce the risk of
developing high albuminuria by one-third compared with
the standard of care in people with type 1 diabetes29 and
significantly reduce the rate of progression from normoalbuminuria to microalbuminuria in newly diagnosed T2D.30
Current pharmacologic recommendations for managing
CKD in T2D include reducing hyperglycemia and hypertension, reducing cardiovascular risk through management of dyslipidemia with statin therapy, using an ACE
inhibitor or angiotensin receptor blocker (ARB) and most
recently, using sodium-glucose co-transporter-2 inhibitors
(SGLT2is) or glucagon-
like peptide-
1 receptor agonists
(GLP-1RAs).2 ACE inhibitors and ARBs are not recommended for the primary prevention of CKD; however, they
are recommended as separate treatments to help preserve
kidney function in all people with T2D and persistent albuminuria (ie, persistent UACR >30 mg/g).1 2 ACE inhibitors
and ARBs are potent antihypertensive agents that counter
the vasoconstrictive effects of angiotensin II, causing
selectively greater vasodilatation of the efferent arterioles
of the glomeruli, thereby reducing intraglomerular pressure.1 ACE inhibitors and ARBs have also been shown to
provide kidney protection independent of blood pressure
control.31 32
SGLT2is and GLP-1RAs have demonstrated reduced risk
of CKD progression in people with T2D in several clinical
trials.33–38 Improved kidney outcomes in people with T2D,
eGFR <60 mL/min/1.73 m2, and either established cardiovascular disease or cardiovascular risk factors,37 and reduced
risk of kidney failure and cardiovascular events in patients
with CKD regardless of T2D status,38 39 have resulted in
SGLT2is being the recommended first-line glucose-lowering
medication, with or without metformin and regardless of
glucose control levels in people with CKD and T2D when
eGFR is ≥30 mL/min/1.73 m2 and UACR is >300 mg/g.1 40
A proposed mechanism for SGLT2is is improving
the intrarenal hemodynamics, which protects the
glomeruli from high-pressure damage. This occurs via
4

tubuloglomerular feedback from the macula densa,
leading to constriction of the afferent arteriole or dilation
of the efferent arteriole.41 Novel approaches to slowing
the progression of CKD in people with T2D involve the
pharmacologic blockade of mineralocorticoid receptor
(MR) overactivation in the kidney.42 MR overactivation
is known to exacerbate inflammation and fibrosis in the
kidneys, the heart, and the vascular system.42 Finerenone,
a novel, selective, non-
steroidal, MR antagonist that
blocks MR overactivation, has demonstrated significant
dose-
dependent reductions in albuminuria in people
with T2D and CKD,43 as well as significantly reducing the
risk of kidney failure, sustained ≥40% decline in eGFR, or
renal death (composite endpoint), and other cardiovascular outcomes in people with CKD and T2D in Finerenone in Reducing Kidney Failure and Disease Progression
in Diabetic Kidney Disease (FIDELIO-DKD).44 In addition, UACR reductions were demonstrated with finerenone versus placebo (−34.7% vs −4.7%).44 Finerenone
in Reducing Cardiovascular Mortality and Morbidity
in Diabetic Kidney Disease (FIGARO-DKD), a recently
completed successful companion phase III trial to FIDELIO-DKD, met its composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus
placebo in people with CKD and T2D.44 45 Despite also
showing reduced albuminuria in people with T2D and
CKD,1 the steroidal MR antagonists spironolactone and
eplerenone are currently underused because of difficulties in managing severe hyperkalemia and worsening of
kidney function.46
Ethnic minority representation varies across these clinical trials but is consistently low compared with Caucasian
representation; this is not CKD-specific but a global and
societal issue that needs to be addressed across all forms
of healthcare. For example, African Americans account
for 35% of people with CKD,47 yet in large CKD studies
such as Canagliflozin and Renal Events in Diabetes
with Established Nephropathy Clinical Evaluation
(CREDENCE), Dapagliflozin and Prevention of Adverse
Outcomes in Chronic Kidney Disease (DAPA-CKD), and
FIDELIO-
DKD, these patients accounted for 5%, 4%,
and 5% of the trial population, respectively.38 39 44
Assessment of albuminuria is an important component of entry criteria for clinical trials, and its use as a
predictor of efficacy should be assessed. Clinical trials
in people with CKD and T2D typically include UACR
measurements as part of the study entry criteria; however,
criteria often vary hugely between studies.38 39 43 44 A
recent meta-analysis supported the role of albuminuria
as a surrogate endpoint in clinical trials of progression
of CKD, with a reduction in albuminuria of >30% associated with substantial reductions in the risk of ESKD.48
Proteinuria may contribute to worsening kidney function by overloading the tubular epithelial cells leading
to intrarenal activation of complement, resulting in
interstitial inflammation predominantly mediated by
macrophages and sustained fibrogenesis.49 As such,
remission of albuminuria (defined as reversal of UACR
BMJ Open Diab Res Care 2022;10:e002806. doi:10.1136/bmjdrc-2022-002806
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(either type 1 or type 2), and 10 years for diabetes
alone (either type 1 or type 2; figure 2).26 Patients with
high albuminuria may die of cardiovascular events
before developing ESKD.20
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ALBUMINURIA AS A TARGET FOR INTERVENTION
Microalbuminuria (UACR <300 mg/g) has been reported
in association with impaired fasting glucose and impaired
glucose tolerance,51 with a prevalence of 15.5% in people
with pre-diabetes.51 Correlation between the presence of
microalbuminuria in people with pre-diabetic conditions
and progression towards T2D suggests that screening of
albuminuria in the general population may be beneficial
for the early prevention of kidney damage.51
Reducing albuminuria may slow progression of CKD
and should, therefore, be considered as a separate target
for kidney-protective therapy. A meta-analysis of data from

41 clinical trials that included participants with diabetes
(71%), glomerular disease (4.4%) and other CKD (25.2%)
demonstrated that decreasing albuminuria is associated
with a reduced risk for developing the clinical endpoint (a
composite of ESKD, doubling of serum creatinine concentration, or eGFR <15 mL/min/1.73 m²), predictive of CKD
progression.48 This is in addition to monitoring cardiovascular risks using well-established surrogate endpoints, such
as glycated hemoglobin for glucose lowering, blood pressure for control of hypertension, and low-density lipoprotein cholesterol for efficacy of lipid lowering.52
Optimum patient management requires regular
screening of people with T2D to ensure early identification of CKD, followed by targeted intervention to reduce
albuminuria (ie, with the use of SGLT2is and GLP-1RAs)
and stabilize eGFR, along with continued regular monitoring.1 53 A proposed algorithm for the optimum management of CKD in T2D using albuminuria as a target is
presented in figure 3. However, barriers to albuminuria
testing exist, including confusion caused by the similarity
of test names and results. For example, the typical range
of results for UACR and urine albumin (UALB) is similar,
but the UACR test measures albumin content relative to
creatine (in units of mg/g) while the UALB test measures
total albumin in urine (in units of mg/dL).54 Other barriers
include a lack of understanding of testing guidelines and

Figure 3 Proposed algorithm for the optimum management of CKD in T2D using albuminuria as a target.2 65 †Exercise
(strenuous exercise within 24 hours of sample collection), infection (septicemia or other conditions increasing vascular
permeability, symptomatic urinary tract infection), fever, congestive heart failure, marked hyperglycemia, menstruation, upright
posture (orthostatic proteinuria causing transient elevation in UACR), and marked hypertension may elevate UACR independent
of kidney damage. A, albuminuria category; ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney
disease; DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; G, GFR category; GLP-1RA,
glucagon-like peptide-1 receptor agonist; RAS, renin–aldosterone system; SGLT2i, sodium-glucose co-transporter-2 inhibitor;
T2D, type 2 diabetes; UACR, urine albumin-to-creatinine ratio.
BMJ Open Diab Res Care 2022;10:e002806. doi:10.1136/bmjdrc-2022-002806
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to normoalbuminuria or <30 mg/g creatinine and a
reduction in UACR by ≥30% from baseline at two consecutive time points) was used as the primary endpoint
in the Esaxerenone (CS-3150) in Patients with Type 2
Diabetes and Microalbuminuria trial, which investigated
the use of esaxerenone, a non-steroidal MR antagonist.50
Despite evidence for the utility of albuminuria, regulatory authorities place more emphasis on GFR thresholds
over UACR, currently accepting a 30%–40% GFR decline
as a surrogate endpoint for kidney failure in clinical trials
of kidney disease progression. However, this may not be
appropriate for drugs targeted at early stages of CKD or
with potential hemodynamic effects.17
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Method

Urine albumin-to-
creatinine ratio;
screening*†

Pros

► Guideline-preferred

Cons

Urine albumin (24-hour
urine albumin test)

Urine dipsticks sensitive
for albuminuria‡

Total protein
measurements (urine
protein-to-creatinine
ratio)§

► Capable of specific and ► Convenient.
► Less expensive.
method.
precise quantification at ► Less expensive.
low concentrations, and
► Capable of specific and
of producing quantitative
precise quantification at
results over the clinically
low concentrations and
relevant range.
of producing quantitative
results over the clinically
relevant range.
► Provides a more specific
and sensitive measure
of changes in glomerular
permeability than urinary
total protein.
► Measurement may be
► Method may be
► Method of measuring
► Do not give equal
influenced by several
burdensome and time
albumin alone.
analytical specificity and
factors;¶ therefore,
consuming and adds
– Measurement of
sensitivity for all proteins
repeat tests are required,
little to prediction or
albumin alone without
that can contribute to
with 2 of 3 abnormal
accuracy.
simultaneously
diverse estimates of
measurements reported ► Measurement may be
measuring urine
proteinuria prevalence.
within a period of
creatinine is
influenced by several
► Not as specific or
3–6 months before a
susceptible to
factors;¶ therefore,
sensitive a measure of
patient is considered to
false-negative
repeat tests are required,
changes in glomerular
have high albuminuria
and false-positive
with 2 of 3 abnormal
permeability as
(figure 3).
determinations as a
measurements reported
UACR, thus not as
result of variation in
within a period of
accurate in detecting
urine concentration
3–6 months before a
low concentrations
due to hydration.
patient is considered to
of albumin indicative
– Simultaneous
have high albuminuria
of the early stages of
measurement of
(figure 3).
kidney damage or kidney
creatinine allows
disease progression.
more accurate
results.

*Screening, as measured by a spot urine sample, is done annually; however, patients with UALB >30 mg/g creatinine or an eGFR <60 mL/
min/1.73 m2 should be monitored twice annually to guide therapy.11
†Albumin is measured using immunologic assays by diagnostic laboratories and albumin concentration reported as a ratio to urinary
creatinine concentration (mg/mmol or mg/g).11
‡Urine dipstick test results may vary depending on the manufacturer and are affected by the urine pH. The results are also operator
dependent and may be affected by colored compounds in urine (ie, bilirubin and drugs such as ciprofloxacin, chloroquine). This test cannot
reliably distinguish between proteinuria categories and has a low diagnostic accuracy for proteinuria detection.2
§Most laboratories use either turbidimetric or colorimetric methods to measure total protein.2
¶Exercise (strenuous exercise within 24 hours of sample collection), infection (septicemia or other conditions increasing vascular
permeability, symptomatic urinary tract infection), fever, congestive heart failure, marked hyperglycemia, menstruation, upright posture
(orthostatic proteinuria causing transient elevation in UACR), and marked hypertension may elevate UACR independent of kidney damage.11
ADA, American Diabetes Association; eGFR, estimated glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes;
UACR, urine albumin-to-creatinine ratio; UALB, urine albumin.

which tests to order; infrequent physician visits by patients
or avoidance of treatment; and methodologic issues, such as
urine collection instructions, requirement for specific urine
cups, or an inadequate patient recall system when patients
fail to provide a urine sample.54 55 The guideline-preferred
method of screening is annual testing of albuminuria using
the accurate and cost-effective UACR test (table 1).2 11 56
Methods of measuring albuminuria are not standardized; however, KDIGO guidelines recommend
6

standardization against a serum-based calibrant (CRM
470), with albumin measured using immunologic assays
capable of specific and precise quantification at low
concentrations and of producing quantitative results over
the clinically relevant range.2 Alternate methods, such as
a 24-hour UALB test, are available; however, this test is
more burdensome (table 1).2 11 The use of urine dipsticks
offers a convenient, cost-effective method of measuring
albuminuria alone (table 1).2 11 However, the use of urine
BMJ Open Diab Res Care 2022;10:e002806. doi:10.1136/bmjdrc-2022-002806
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Table 1 Methods for testing albuminuria as recommended by KDIGO and ADA guidelines2 11 54 57
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DISCUSSION AND CONCLUSIONS
Albuminuria is a key marker of kidney damage and
cardiorenal risk, and it is important to perform periodic
tests for albuminuria in people with T2D, both to detect
CKD and to monitor its progression. The CREDENCE
(CKD and T2D population) and DAPA-CKD (CKD and
mixed T2D and non-T2D population) trials of SGLT2is
have shown that the presence of high albuminuria at
baseline is predictive of elevated risk for future hard
kidney outcomes;38 39 the Heart Outcomes Prevention
Evaluation (HOPE) study identified albuminuria as a
continuous risk factor for all-cause mortality and cardiovascular mortality;59 and in a meta-analysis of clinical trial
data, lowering of albuminuria with SGLT2is correlated
with delayed onset of hard kidney outcomes such as
kidney replacement therapy.60 61 An increased focus on
routine systematic testing for albuminuria in clinical
practice is important to address the current suboptimal
rates and overcome existing barriers for albuminuria
testing. There has been a long-standing perception of
no utility in screening for CKD. For decades, there were
no interventions apart from ACE inhibitors and ARBs;
often prescribed for hypertension or heart failure that
could address a decline in kidney function. However,
this is changing with an evolving landscape: SGLT2is are
now indicated for CKD in people with T2D62 and positive
outcomes are being reported for new agents that specifically target kidney damage (eg, non-steroidal MR antagonists). The KDIGO and American Diabetes Association
guidelines now recommend that people with CKD and
T2D, and an eGFR ≥30 mL/min/1.73 m2 would benefit
from the use of SGLT2is, with or without metformin; GLP-
1RAs recommended as a preferred additional therapy
based on patient preferences, comorbidities, cost, and
eGFR status1 because these therapies appear to reduce
the risk of CKD progression, cardiovascular events, and
hypoglycemia.11
BMJ Open Diab Res Care 2022;10:e002806. doi:10.1136/bmjdrc-2022-002806

The importance of education and awareness around
albuminuria screening is underscored by the launch of a
new public awareness initiative by the US Department of
Health and Human Services, the National Kidney Foundation, and the American Society of Nephrology, which
aim to provide education about the risks of CKD and
promote the early detection, treatment and management
of CKD to improve patient outcomes.63 Furthermore, a
majority of CKD burden is concentrated in geographies
with the lowest sociodemographic index,64 where early
detection using cost-effective methodologies and early
intervention could have a significant impact on reducing
disease burden.
We strongly believe that the time is right for a far more
aggressive and interventional approach to CKD in T2D
that goes all the way from education and awareness to
appropriate and regular screening and follow-up. This is
particularly relevant in view of both the recent executive
order on kidney diseases and the availability, for the first
time, of novel therapies that could effectively prevent the
progression of CKD.
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dipsticks is susceptible to false results with poor sensitivity
for UACR ≥30 mg/g detection (~62%; 95% CI 50.9 to
72.0).2 57 58 Combining urine dipstick measurements for
albumin with simultaneous measurement of creatinine
could ensure a higher level of accuracy as this will correct
for variations in albumin concentration that is highly
dependent on hydration status.11 In addition, assays that
measure total protein, such as colorimetric protein assays,
may be used.2 11 However, it is important to note that
UALB measurements provide a more specific and sensitive measure of changes in glomerular permeability than
urinary total protein, and they enable early detection
of low concentrations of albumin as a marker of kidney
damage and the progression of kidney disease (table 1).2
Therefore, as kidney function declines, it is recommended that testing be carried out more frequently,2
with repeat testing of albuminuria in addition to eGFR
measurements recommended to assess disease progression or response to treatment (figure 3).2
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